x

Posted 27 October, 2022

INTELLIGENT BIO SOLUTIONS INC. appointed Harry Simeonidis as new CEO

Nasdaq:GBS appointed new Chief Executive Officer Harry Simeonidis in a 8-K filed on 27 October, 2022.


  On October 26, 2022, Intelligent Bio Solutions Inc., a Delaware corporation formerly known as GBS Inc. (the "Company"), elected Harry Simeonidis, who currently serves as the Company's President Asia Pacific, Sales and Marketing, as the Company's President and Chief Executive Officer, effective as of October 26, 2022.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of INTELLIGENT BIO SOLUTIONS INC.
Health Care/Life Sciences • Medical Equipment/Supplies
Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.
Market Cap
$12.0M
View Company Details
INTELLIGENT BIO SOLUTIONS INC. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On October 26, 2022, Intelligent Bio Solutions Inc., a Delaware corporation formerly known as GBS Inc. (the "Company"), elected Harry Simeonidis, who currently serves as the Company's President Asia Pacific, Sales and Marketing, as the Company's President and Chief Executive Officer, effective as of October 26, 2022. Mr. Simeonidis succeeds Dr. Steven Boyages, who is stepping down as the Company's Interim Chief Executive Officer. Dr. Boyages will continue to serve as the Chairman of the Company's board of directors (the "Board").


Mr. Simeonidis, age 54, had served as the Company's President Asia Pacific, Sales and Marketing since October 2021. From September 2017 until October 2021, he served as the Company's President and a member of the Company's Board, and from January 2020 until October 2021, he served as the Chief Executive Officer of the Company. Mr. Simeonidis has more than 26 years of experience in senior management roles in healthcare, pharmaceutical and life sciences businesses across the APAC Region. Previously, from March 2017 to December 2019, he served as the General Manager of FarmaForce Limited, an Australian company listed on the Australian Stock Exchange. From April 2015 to March 2017, Mr. Simeonidis operated a private consulting firm, offering services predominantly to clients from the healthcare sector in Australia. From 2013 to April 2015, Mr. Simeonidis was General Manager of Surgery, Asia Pacific, at GE Healthcare. From 2003 to 2012, Mr. Simeonidis was the CEO for Australia and New Zealand at GE Healthcare.